Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $91.57 million. The enterprise value is $71.22 million.
Important Dates
The next estimated earnings date is Tuesday, May 26, 2026, after market close.
| Earnings Date | May 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 3.26 million shares outstanding. The number of shares has increased by 68.18% in one year.
| Current Share Class | 3.26M |
| Shares Outstanding | 3.26M |
| Shares Change (YoY) | +68.18% |
| Shares Change (QoQ) | +9.56% |
| Owned by Insiders (%) | 10.67% |
| Owned by Institutions (%) | 22.32% |
| Float | 2.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.47 |
| Forward PS | 9.43 |
| PB Ratio | 3.57 |
| P/TBV Ratio | 3.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.74, with a Debt / Equity ratio of 0.16.
| Current Ratio | 2.74 |
| Quick Ratio | 2.64 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -74.29 |
Financial Efficiency
Return on equity (ROE) is -121.11% and return on invested capital (ROIC) is -58.16%.
| Return on Equity (ROE) | -121.11% |
| Return on Assets (ROA) | -44.56% |
| Return on Invested Capital (ROIC) | -58.16% |
| Return on Capital Employed (ROCE) | -92.35% |
| Weighted Average Cost of Capital (WACC) | 16.92% |
| Revenue Per Employee | $947,103 |
| Profits Per Employee | -$917,310 |
| Employee Count | 29 |
| Asset Turnover | 0.74 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Cue Biopharma has paid $500,000 in taxes.
| Income Tax | 500,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +26.50% in the last 52 weeks. The beta is 2.39, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.39 |
| 52-Week Price Change | +26.50% |
| 50-Day Moving Average | 15.01 |
| 200-Day Moving Average | 16.88 |
| Relative Strength Index (RSI) | 58.97 |
| Average Volume (20 Days) | 1,347,646 |
Short Selling Information
The latest short interest is 288,887, so 8.87% of the outstanding shares have been sold short.
| Short Interest | 288,887 |
| Short Previous Month | 7.54M |
| Short % of Shares Out | 8.87% |
| Short % of Float | 9.93% |
| Short Ratio (days to cover) | 0.32 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $27.47 million and -$26.60 million in losses. Loss per share was -$8.42.
| Revenue | 27.47M |
| Gross Profit | -7.38M |
| Operating Income | -26.52M |
| Pretax Income | -26.10M |
| Net Income | -26.60M |
| EBITDA | -25.56M |
| EBIT | -26.52M |
| Loss Per Share | -$8.42 |
Full Income StatementBalance Sheet
The company has $28.23 million in cash and $4.20 million in debt, with a net cash position of $24.03 million or $7.38 per share.
| Cash & Cash Equivalents | 28.23M |
| Total Debt | 4.20M |
| Net Cash | 24.03M |
| Net Cash Per Share | $7.38 |
| Equity (Book Value) | 26.43M |
| Book Value Per Share | 8.21 |
| Working Capital | 23.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$21.69 million and capital expenditures -$177,000, giving a free cash flow of -$21.86 million.
| Operating Cash Flow | -21.69M |
| Capital Expenditures | -177,000 |
| Depreciation & Amortization | 958,000 |
| Net Borrowing | -4.50M |
| Free Cash Flow | -21.86M |
| FCF Per Share | -$6.72 |
Full Cash Flow StatementMargins
Gross margin is -26.86%, with operating and profit margins of -96.56% and -96.85%.
| Gross Margin | -26.86% |
| Operating Margin | -96.56% |
| Pretax Margin | -95.03% |
| Profit Margin | -96.85% |
| EBITDA Margin | -93.07% |
| EBIT Margin | -96.56% |
| FCF Margin | n/a |
Dividends & Yields
Cue Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -68.18% |
| Shareholder Yield | -68.18% |
| Earnings Yield | -27.93% |
| FCF Yield | -22.95% |
Analyst Forecast
The average price target for Cue Biopharma is $120.00, which is 326.59% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $120.00 |
| Price Target Difference | 326.59% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 17.36% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 24, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Apr 24, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Cue Biopharma has an Altman Z-Score of -10.72 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.72 |
| Piotroski F-Score | 4 |
